Clinical Trial Update: To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating SG301 SC injection for systemic lupus erythematosus is currently recruiting to assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SG301 SC injection (SG301)

Snippet

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 2 | Status: RECRUITING